They did achieve only 20% CR at 12 months in their recent BCG-unresponsive NMIBC trial. And many of the patients suffered serious adverse effects, including one treatment-related death. And yet the FDA granted approval. Theralase should achieve far better results.
Market Data 
Markets 
AI
